Sign in
SuspendedPhase 2

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

Key facts

Who runs it
Institut Paoli-Calmettes
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Phase 2
People taking part
35 people, planned
Started
22 May 2024
Expected to end
Jan 2029
Type of study
Interventional
Treatments tested
  • Dasatinib
Record updated
1 October 2026
Why it stopped
Planned interim analyse

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Confirmed diagnosis of AML except Philadelphia chromosome-positive AML (Ph+) and acute promyelocytic leukemia (AML M3)
  • Age ≥ 18 years
  • ECOG ≤3
  • VEN-AZA refractory defined as no response after two cycles of VEN-AZA whatever the dose and the treatment duration
  • Signed informed consent form
  • Affiliation to a social security system, or beneficiary of such a system

Who cannot take part

  • Patient eligible to a targeted therapy having a market authorization
  • Heart failure
  • Liver failure
  • Kidney failure
  • Positive for HIV (detectable viral load), Hepatitis B or C
  • No efficient contraception for the women of childbearing age
  • Central nervous system involvement
  • Contraindication to DASATINIB
  • Pregnant or breastfeeding woman
  • Emergency situation person or not able to express his/her informed consent
  • Patient under a legal protection measure (adult under guardianship, curatorship or safeguard of justice)
  • Inability to undergo the clinical trial medical follow-up for geographical, social or psychological reasons

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn about the efficacy of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE. The main question it aims to answer is to assess the tumor response after 2 cycles of DASATINIB monotherapy treatment for patients with chemotherapy-ineligible acute myeloid leukemia refractory to VENETOCLAX-AZACITIDINE therapy.

Read full original descriptionShow less

Participants will be given DASATINIB treatment up to 3 months. Response will be assessed by a myelogram and a complete blood count at the end of every cycle. Follow up will last 6 months.

The group in the trial

  • DASATINIBTreatment being tested

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of DASATINIB Monotherapy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Record updated
1 October 2026